Loading
Life sciences · Journal article
Bioactive Materials · September 15, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
The spatiotemporal distribution of gaseous mediators is critical for maintaining physiological functions. Biofilms both contain gas-producing bacteria and possess complex architectures that reshape gaseous mediator distribution. However, whether biofilm pathogenicity is linked to such gaseous regulation remains unclear. In this study, we reveal that extracellular DNA (eDNA) within the biofilm matrix contributes to the local retention and enrichment of H2S. This enrichment stabilizes eDNA, strengthens biofilm barriers, impedes gas clearance, promotes bacterial persistence, and induces macrophage immunosuppression, creating a reciprocally protective defensive loop. To dismantle this defense, we engineered a stepwise-responsive biohybrid system in which probiotic-derived engineered minicells actively target hypoxic biofilm regions, while H2S-triggered nanoparticle degradation enables deeper matrix penetration and concurrent H2S scavenging. The retained minicells then catalyze in situ glucose oxidation to generate H2O2, which, together with Fe2+-mediated Fenton-like reactions, degrades eDNA and collapses the biofilm. This strategy eradicates persistent bacteria, reverses immunosuppression, and provides a therapeutic strategy to reduce recurrence and optimize refractory infection treatments.